hydroxyurea has been researched along with Anemia, Cooley's in 199 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination of hydroxyurea with l-carnitine or magnesium could be more effective in improving hematologic parameters and cardiac status in patients with beta-thalassemia intermedia than hydroxyurea alone." | 9.14 | Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. ( Amoozgar, H; Behmanesh, F; Borzouee, M; Haghpanah, S; Karimi, M; Mohammadi, F; Samani, SM, 2010) |
| "Some, but not all, beta-thalassemia/hemoglobin E (beta-thal/HbE) patients respond to hydroxyurea treatment." | 9.11 | In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. ( Chuncharunee, S; Fucharoen, S; Kongnium, W; Rodgers, GP; Sanmund, D; Watanapokasin, Y; Winichagoon, P, 2005) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 9.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| " We aimed to study the cost effectiveness of two treatments, including blood transfusion and hydroxyurea, in patients with beta-thalassemia intermedia in south of Iran referred to a referral center affiliated to Iran, Shiraz University of Medical Sciences in 2015." | 7.88 | Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. ( Haghpanah, S; Karimi, M; Keshavarz, K; Mirzaei, Z; Ravangard, R, 2018) |
| "In this study, we hypothesize that hydroxyurea could provide an additional benefit as a free radical scavenger and/or iron chelator in β-thalassemia patients with iron overload." | 7.83 | Can hydroxyurea serve as a free radical scavenger and reduce iron overload in β-thalassemia patients? ( Chandrakala, S; Colah, R; Ghosh, K; Italia, K, 2016) |
| "The findings suggested role of hydroxyurea in the pathogenesis of these ulcers, and that it must be immediately discontinued to prevent further damage to the digestive mucosa." | 7.80 | Hydroxyurea and colonic ulcers: a case report. ( Atichartakarn, V; Boonyawat, K; Nitiyanant, P; Wongwaisayawan, S, 2014) |
| "We aimed at evaluating the effect of long-term use of hydroxyurea (HU) on gonad function in patients with beta-thalassemia intermedia (beta-TI) in Iran." | 7.78 | Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea. ( Haghpanah, S; Javad, P; Karamizadeh, Z; Karimi, M; Zekavat, OR, 2012) |
| " Pharmacologic agents such as hydroxyurea have been known to enhance the production of fetal hemoglobin, and also an increase in total hemoglobin level has been repeatedly reported during hydroxyurea treatment in patients with sickle cell disease and in several patients with intermediate beta-thalassemia." | 7.75 | Hydroxyurea therapy in 49 patients with major beta-thalassemia. ( Basi, A; Eslami, SM; Razavi, SM; Shakeri, R; Zamani, F, 2009) |
| "Although a relatively small number of previous studies suggest a modest response to hydroxyurea (HU) therapy in beta-thalassemia, more recent investigations have revealed that some transfusion-dependent patients can become transfusion-independent following HU therapy." | 7.74 | Response to hydroxyurea therapy in beta-thalassemia. ( Dgany, O; Elhasid, R; Koren, A; Kransnov, T; Levin, C; Palmor, H; Tamary, H; Zalman, L, 2008) |
| "Due to genetic heterogeneity of beta-thalassemia (beta-thal) patients, several efforts have been undertaken to determine the efficacy of hydroxyurea treatment." | 7.73 | Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture. ( Fucharoen, S; Muta, K; Sanmund, D; Watanapokasin, R; Winichagoon, P, 2006) |
| "We report a 24 years old patient with thalassaemia intermedia and gynecomastia, complicated by paraplegia and urinary/fecal incontinence due to spinal cord compression by an extramedullary erythropoiesis (EE) mass, treated with long-term hydroxyurea (HU)." | 7.72 | Paraplegia due to spinal cord compression by extramedullary erythropoietic tissue in a thalassaemia intermedia patient with gynecomastia secondary to cirrhosis: successful treatment with hydroxyurea. ( De Sanctis, V; Fortini, M; Gamberini, MR, 2004) |
| "We report a preliminary clinical experience in the use of hydroxyurea (HU) for the treatment of leg ulcers in thalassaemia intermedia patients with associated endocrine complications." | 7.72 | Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. ( De Sanctis, V; Fortini, M; Gamberini, MR, 2004) |
| " He received therapy with hydroxyurea (20 mg/kg/d) because of the presence of extramedullary masses causing paraparesis, neurogenic bladder and impotence." | 7.70 | Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters. ( Amadori, S; Cianciulli, P; di Toritto, TC; Massa, A; Sergiacomi, L; Sorrentino, F, 2000) |
| "A newly developed method of RT-PCR/competitive PCR for measuring the relative and absolute content of globin mRNAs as well as micro-globin chain biosynthetic assay have been used to study the alterations of globin gene expressions in the patients with beta-thalassemia pre- and post-hydroxyurea (HU) treatment." | 7.69 | Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression. ( Chen, MJ; Huang, SZ; Ren, ZR; Rodgers, GP; Schechter, AN; Xu, HP; Zeng, FY; Zeng, YT, 1994) |
| "Hydroxyurea (HU), an inhibitor of DNA synthesis, has been shown to increase fetal hemoglobin (HbF) levels in patients with sickle cell anemia and in some patients with beta-thalassemia." | 7.68 | Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. ( Burke, LP; Fibach, E; Noguchi, CT; Rodgers, GP; Schechter, AN, 1993) |
| "Twenty-three patients with beta-thalassemia major received HU at a mean dose of 16 mg/kg/d." | 6.73 | Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). ( Ansari, SH; Farzana, T; Irfan, M; Mehboob, T; Panjwani, VK; Perveen, K; Shamsi, TS; Siddiqui, FJ; Yousuf, A, 2007) |
| "Effects in patients with beta-thalassemia major are controversial." | 6.71 | Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. ( Abad, MT; Bradai, M; de Montalembert, M; Lamraoui, F; Pissard, S; Skopinski, L, 2003) |
| "However, the efficacy of HU in beta-thalassemia intermedia (TI) is unclear." | 6.45 | Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. ( Bagheri, A; Ehsani, MA; Hedayati-Asl, AA; Rashidi, A; Zeinali, S, 2009) |
| "The aim of this study was to evaluate the tolerance and adverse effects of hydroxyurea (HU) in thalassemia intermedia (TI) patients who had been treated by HU for a period of 10 years." | 5.36 | Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience. ( Cohan, N; Falahi, MJ; Haghpanah, S; Karimi, M; Moosavizadeh, K; Mousavizadeh, K, 2010) |
| "Hydroxyurea (HU) has been known to cause induction of fetal hemoglobin (HbF), but the efficacy of this treatment in beta-thalassemia patients is still unclear." | 5.35 | Hematologic response to hydroxyurea therapy in children with beta-thalassemia major. ( Kvezereli-Kopadze, A; Kvezereli-Kopadze, M; Mestiashvili, I; Mtvarelidze, Z, 2008) |
| "Hydroxyurea (HU) has been shown to reduce the frequency of vaso-occlusive manifestations in both adults and children with sickle cell disease (SCD), and the induction of hemoglobin F (HbF) is thought to be the underlying mechanism responsible for clinical improvement in some patients." | 5.32 | The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. ( Gumruk, F; Gurgey, A; Koc, A, 2003) |
| "Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with l-glutamine, administered alone or with hydroxyurea, than among those who received placebo, with or without hydroxyurea." | 5.27 | A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. ( Bellevue, R; Blake, OA; Gordeuk, VR; Guillaume, E; Hsu, LL; Kanter, J; Lanzkron, S; Lasky, JL; Miller, ST; Neumayr, LD; New, TN; Niihara, Y; Osunkwo, I; Panosyan, EH; Razon, RL; Sadanandan, S; Sarnaik, S; Sieger, L; Smith, WR; Stark, CW; Tran, LT; Vichinsky, EP; Viswanathan, K, 2018) |
| "Combination of hydroxyurea with l-carnitine or magnesium could be more effective in improving hematologic parameters and cardiac status in patients with beta-thalassemia intermedia than hydroxyurea alone." | 5.14 | Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. ( Amoozgar, H; Behmanesh, F; Borzouee, M; Haghpanah, S; Karimi, M; Mohammadi, F; Samani, SM, 2010) |
| "Some, but not all, beta-thalassemia/hemoglobin E (beta-thal/HbE) patients respond to hydroxyurea treatment." | 5.11 | In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. ( Chuncharunee, S; Fucharoen, S; Kongnium, W; Rodgers, GP; Sanmund, D; Watanapokasin, Y; Winichagoon, P, 2005) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 5.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| " Hydroxyurea, EPO preparations, sodium phenylbutyrate, arginine butyrate, and 5-azacytidine/decitabine have shown efficacy in approximately 40% to 70% of sickle cell and beta-thalassemia patients." | 4.84 | Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. ( Perrine, SP, 2008) |
| "Hydroxyurea (HU) has been widely used in clinical practice to manage patients with non-transfusion dependent thalassemia (NTDT)." | 4.12 | The use of hydroxyurea in the real life of MIOT network: an observational study. ( Allò, M; Filosa, A; Maggio, A; Meloni, A; Messina, G; Pepe, A; Pistoia, L; Quarta, A; Quota, A; Ricchi, P; Rigano, P; Rosso, R; Spasiano, A, 2022) |
| " We aimed to study the cost effectiveness of two treatments, including blood transfusion and hydroxyurea, in patients with beta-thalassemia intermedia in south of Iran referred to a referral center affiliated to Iran, Shiraz University of Medical Sciences in 2015." | 3.88 | Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. ( Haghpanah, S; Karimi, M; Keshavarz, K; Mirzaei, Z; Ravangard, R, 2018) |
| "In this study, we hypothesize that hydroxyurea could provide an additional benefit as a free radical scavenger and/or iron chelator in β-thalassemia patients with iron overload." | 3.83 | Can hydroxyurea serve as a free radical scavenger and reduce iron overload in β-thalassemia patients? ( Chandrakala, S; Colah, R; Ghosh, K; Italia, K, 2016) |
| "The findings suggested role of hydroxyurea in the pathogenesis of these ulcers, and that it must be immediately discontinued to prevent further damage to the digestive mucosa." | 3.80 | Hydroxyurea and colonic ulcers: a case report. ( Atichartakarn, V; Boonyawat, K; Nitiyanant, P; Wongwaisayawan, S, 2014) |
| "We aimed at evaluating the effect of long-term use of hydroxyurea (HU) on gonad function in patients with beta-thalassemia intermedia (beta-TI) in Iran." | 3.78 | Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea. ( Haghpanah, S; Javad, P; Karamizadeh, Z; Karimi, M; Zekavat, OR, 2012) |
| " Pharmacologic agents such as hydroxyurea have been known to enhance the production of fetal hemoglobin, and also an increase in total hemoglobin level has been repeatedly reported during hydroxyurea treatment in patients with sickle cell disease and in several patients with intermediate beta-thalassemia." | 3.75 | Hydroxyurea therapy in 49 patients with major beta-thalassemia. ( Basi, A; Eslami, SM; Razavi, SM; Shakeri, R; Zamani, F, 2009) |
| "Although a relatively small number of previous studies suggest a modest response to hydroxyurea (HU) therapy in beta-thalassemia, more recent investigations have revealed that some transfusion-dependent patients can become transfusion-independent following HU therapy." | 3.74 | Response to hydroxyurea therapy in beta-thalassemia. ( Dgany, O; Elhasid, R; Koren, A; Kransnov, T; Levin, C; Palmor, H; Tamary, H; Zalman, L, 2008) |
| "Due to genetic heterogeneity of beta-thalassemia (beta-thal) patients, several efforts have been undertaken to determine the efficacy of hydroxyurea treatment." | 3.73 | Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture. ( Fucharoen, S; Muta, K; Sanmund, D; Watanapokasin, R; Winichagoon, P, 2006) |
| "A young Arab woman with sickle cell-beta0-thalassemia disease developed acute colonic pseudo-obstruction that became chronic but showed some response to hydroxyurea." | 3.72 | Colonic pseudo-obstruction in sickle cell disease. ( Ayyaril, M; Daar, A; Knox-Macaulay, H; Nusrat, N, 2003) |
| "We report a 24 years old patient with thalassaemia intermedia and gynecomastia, complicated by paraplegia and urinary/fecal incontinence due to spinal cord compression by an extramedullary erythropoiesis (EE) mass, treated with long-term hydroxyurea (HU)." | 3.72 | Paraplegia due to spinal cord compression by extramedullary erythropoietic tissue in a thalassaemia intermedia patient with gynecomastia secondary to cirrhosis: successful treatment with hydroxyurea. ( De Sanctis, V; Fortini, M; Gamberini, MR, 2004) |
| "We report a preliminary clinical experience in the use of hydroxyurea (HU) for the treatment of leg ulcers in thalassaemia intermedia patients with associated endocrine complications." | 3.72 | Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. ( De Sanctis, V; Fortini, M; Gamberini, MR, 2004) |
| "We have studied the effects of hydroxyurea on growth and differentiation of early erythroid progenitor cells (BFU-e) from peripheral blood of sickle cell disease patients (five SS and two Hb S/beta-thalassemia) in the presence or absence of exogenous stimulating factors." | 3.71 | Hydroxyurea promotes the reduction of spontaneous BFU-e to normal levels in SS and S/beta thalassemic patients. ( Bincoletto, C; Costa, FF; Perlingeiro, RC; Queiroz, ML; Saad, ST, 2001) |
| " An attempt was made in 10 patients to reduce marrow hyperplasia by using hydroxyurea." | 3.70 | Bone pain in thalassaemia: assessment of DEXA and MRI findings. ( Angastiniotis, M; Aristidou, K; Eracleous, E; Kanakas, A; Pavlides, N; Posporis, T; Yerakaris, M, 1998) |
| " He received therapy with hydroxyurea (20 mg/kg/d) because of the presence of extramedullary masses causing paraparesis, neurogenic bladder and impotence." | 3.70 | Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters. ( Amadori, S; Cianciulli, P; di Toritto, TC; Massa, A; Sergiacomi, L; Sorrentino, F, 2000) |
| "We report the response of three patients with homozygous sickle cell disease and 10 patients with compound HbS/beta-thalassemia (four with beta(o)thal/HbS and six with beta(+)thal/HbS respectively) to hydroxyurea treatment with regards to their serum erythropoietin levels (sEpo)." | 3.70 | Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. ( Loukopoulos, D; Papassotiriou, I; Stamoulakatou, A; Voskaridou, E, 2000) |
| "Three adult patients with beta-thalassemia intermedia were treated with hydroxyurea." | 3.69 | Pharmacologic treatment of thalassemia intermedia with hydroxyurea. ( Hajjar, FM; Pearson, HA, 1994) |
| "A newly developed method of RT-PCR/competitive PCR for measuring the relative and absolute content of globin mRNAs as well as micro-globin chain biosynthetic assay have been used to study the alterations of globin gene expressions in the patients with beta-thalassemia pre- and post-hydroxyurea (HU) treatment." | 3.69 | Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression. ( Chen, MJ; Huang, SZ; Ren, ZR; Rodgers, GP; Schechter, AN; Xu, HP; Zeng, FY; Zeng, YT, 1994) |
| "Hydroxyurea (HU), an inhibitor of DNA synthesis, has been shown to increase fetal hemoglobin (HbF) levels in patients with sickle cell anemia and in some patients with beta-thalassemia." | 3.68 | Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. ( Burke, LP; Fibach, E; Noguchi, CT; Rodgers, GP; Schechter, AN, 1993) |
| " Mild adverse events were reported in 48 (9%) patients and serious adverse events, including cerebral vascular accident and portal vein thrombosis were reported in two patients each." | 3.30 | Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study. ( Ali, M; Ali, Z; Ismail, M; Khan, MTM; Rani, GF; Rehman, IU, 2023) |
| "Hydroxyurea treatment did not alter the blood transfusion volume overall." | 3.11 | A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. ( Attanayaka, K; Hameed, N; Manamperi, A; Mettananda, C; Mettananda, S; Perera, L; Premawardhena, A; Rodrigo, R; Silva, I; Wickramarathne, N; Wickramasinghe, N; Yasara, N, 2022) |
| "Hydroxyurea, which has shown to induce fetal haemoglobin synthesis in human erythroid cells, is currently recommended for the treatment of sickle cell disease." | 2.94 | Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial. ( Manamperi, A; Mettananda, C; Mettananda, S; Premawardhena, A; Wickramarathne, N; Yasara, N, 2020) |
| "Hydroxyurea is an effective drug to increase fetal γ-globin (HbF) expression, replacing the missing adult β-globin." | 2.90 | Pharmacoproteomics Profiling of Plasma From β-Thalassemia Patients in Response to Hydroxyurea Treatment. ( Ansari, SH; Shamsi, TS; Zarina, S; Zohaib, M; Zubarev, RA, 2019) |
| "Gastritis was graded as severe in three subjects at 40 mg/kg and was considered the dose-limiting toxicity." | 2.78 | A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. ( Abboud, MR; Ataga, KI; Buchanan, GR; El-Beshlawy, A; Ghalie, RG; Inati, A; Kutlar, A; Perrine, SP; Reid, ME; Smith, H; Taher, AT, 2013) |
| " No serious adverse events necessitating discontinuation of therapy in both groups." | 2.78 | Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. ( Adly, AA; Elalfy, MS; Elghamry, IR; Elhenawy, YI; Ismail, EA, 2013) |
| "One hundred fifty-two patients with β-thalassemia major received HU at a mean dose of 16 mg/kg/d." | 2.76 | Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. ( Ansari, SH; Ashraf, M; Bohray, M; Erum, S; Farzana, T; Mehboob, T; Perveen, K; Shamsi, TS, 2011) |
| "Seventy-nine patients-[38-beta thalassemia intermedia-(group I), 41-beta thalassemia major-(group II)] on hydroxyurea therapy were followed-up for 20-24months." | 2.74 | Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. ( Colah, RB; Ghosh, K; Italia, KY; Jijina, FJ; Merchant, R; Nadkarni, AH; Nair, SB; Panjwani, S; Sawant, PM, 2009) |
| "Twenty-three patients with beta-thalassemia major received HU at a mean dose of 16 mg/kg/d." | 2.73 | Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). ( Ansari, SH; Farzana, T; Irfan, M; Mehboob, T; Panjwani, VK; Perveen, K; Shamsi, TS; Siddiqui, FJ; Yousuf, A, 2007) |
| "Effects in patients with beta-thalassemia major are controversial." | 2.71 | Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. ( Abad, MT; Bradai, M; de Montalembert, M; Lamraoui, F; Pissard, S; Skopinski, L, 2003) |
| "Thirty-seven patients with beta-thalassemia intermedia were enrolled to assess response to HU therapy." | 2.71 | Hydroxyurea in thalassemia intermedia--a promising therapy. ( Chatterjee, TC; Choudhry, DR; Choudhry, VP; Dixit, A; Kabra, M; Mahapatra, M; Mishra, P; Saxena, R; Tyagi, S, 2005) |
| "Twenty patients with thalassemia intermedia were given HU (10-20 mg/kg) and responses were evaluated over a one year period." | 2.71 | Do alpha deletions influence hydroxyurea response in thalassemia intermedia? ( Arora, S; Choudhry, VP; Dixit, A; Kabra, M; Mahapatra, M; Panigrahi, I; Saxena, R, 2005) |
| "Beta thalassemia major (TM) is the most frequent form of transfusion-dependent inherited anemia in India." | 2.66 | Thalassemia: Common Clinical Queries in Management. ( Bansal, D; Lal, A, 2020) |
| "Hemoglobin E-beta thalassemia (Hb E/β-thalassemia) is a distinct, yet common, type of β-thalassemia, in which the patient co-inherits a β-thalassemia allele from one parent, and a structural variant, Hb E, from the other parent." | 2.55 | Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis. ( Algiraigri, AH; Kassam, A, 2017) |
| "Hydroxyurea has been used to increase foetal haemoglobin level; however, its efficacy in reducing transfusion, chronic anaemia complications and its safety need to be established." | 2.53 | Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. ( Foong, WC; Ho, JJ; Loh, CK; Viprakasit, V, 2016) |
| " We selected studies on randomized trials, quasi experimental trials (before and after design), case reports (with 1-5 cases), side effect studies in patients with β-TM, studies related to the mechanism of action and toxicity when used in patients with other hemoglobinopathies." | 2.50 | The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012. ( Alipur, A; Hedayatizadeh-Omran, A; Kosaryan, M; Zafari, M, 2014) |
| "Hydroxyurea (HU) is a drug that induces fetal hemoglobin production." | 2.49 | Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? ( Banan, M, 2013) |
| "However, the efficacy of HU in beta-thalassemia intermedia (TI) is unclear." | 2.45 | Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. ( Bagheri, A; Ehsani, MA; Hedayati-Asl, AA; Rashidi, A; Zeinali, S, 2009) |
| "Hydroxyurea (HU) is an antineoplastic agent that enhances fetal hemoglobin." | 2.45 | Hydroxyurea in the management of thalassemia intermedia. ( Karimi, M, 2009) |
| "Homozygous beta thalassemia affects thousands of people around the world." | 2.40 | Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea. ( Dover, GJ, 1998) |
| " We did not observe any significant adverse effects during the treatment period." | 1.91 | Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India. ( Chandak, GR; Lad, H; Nahrel, R; Naskar, S; Patra, PK; Punyasri Pasupuleti, SKDB; Sihare, P, 2023) |
| "Hydroxyurea (HU) has demonstrated promising outcomes; additionally, thalidomide has also shown improvement in hemoglobin (Hb) levels for patients with β-thalassemia in some studies." | 1.72 | Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. ( Adil, SO; Ansari, AH; Ansari, I; Ansari, SH; Ansari, UH; Farooq, F; Hussain, Z; Khawaja, S; Masqati, NU; Sattar, A; Wasim, M; Zohaib, M, 2022) |
| "Hydroxyurea (HU) is an effective drug to increase fetal γ-globin gene (Hb F) expression, replacing the missing adult β-globin gene." | 1.72 | Treatment with Hydroxyurea Leads to Fetal Hemoglobin Reactivation through ( Miri-Moghaddam, E; Nomiri, S; Parsasefat, M; Safarpour, H, 2022) |
| "Sickle beta+thalassemia is considered to be a mild form of sickle cell disease." | 1.72 | Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia. ( Bhasin, N; Desoky, SM; Price, N, 2022) |
| " However, this study found that the poor potency and oral bioavailability of compound 1 limits the development of this inducer for clinical use." | 1.62 | Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease. ( Chen, CT; Chou, YC; Hsieh, MY; Hsu, T; James Shen, CK; Jiaang, WT; Kung, FC; Lai, ZS; Lin, CH; Lu, CT; Yeh, TK, 2021) |
| "Only pediatrics patients with beta thalassemia major and those who were on chemotherapy treatment and post-transplant patient were included in this study." | 1.62 | Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance. ( Al-Quteimat, O; Ali, K; Ansari, SH; Jahan, N; Malhi, SM; Naseem, R; Shamsi, TS; Wajdi, M, 2021) |
| " No severe adverse effects was reported by patients of any group." | 1.62 | Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India. ( Baul, SN; Chakrabarti, P; De, R; Dolai, TK; Ghosh, P; Jain, M; Mandal, PK, 2021) |
| " All patients were regularly examined and monitored for the occurrence of any adverse event (AE) of HU." | 1.62 | Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience. ( Aramesh, A; Bahmanimehr, A; Daryanoush, S; Haghpanah, S; Karimi, M; Zarei, T, 2021) |
| "Hydroxyurea was shown to have a variable favorable effect on β-thal in Yemeni patients." | 1.56 | Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients. ( Al-Hadi, AM; Al-Nood, HA; Al-Nood, RM; Ghanem, NS, 2020) |
| "Hydroxyurea was started at an initial dose of 10 mg/kg of body weight/day on 110 transfusion-dependent HbE-β thalassaemia patients." | 1.51 | Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia. ( Bandyopadhyay, A; Bhattacharyya, M; Biswas, S; Ghosh, K; Nag, A; Ray, R; Roy, K, 2019) |
| "Hydroxyurea was started at a baseline dose in 82 transfusion-dependent HbE-β-thalassaemia patients." | 1.51 | Alpha Globin Gene Mutation: A Major Determinant of Hydroxyurea Response in Transfusion-Dependent HbE-β-Thalassaemia. ( Bandyopadhyay, A; Bhattacharyya, M; Biswas, S; Ghosh, K; Ray, R; Roy, K, 2019) |
| "Hydroxyurea is a highly effective treatment for SCD but less so for β-thalassemia, and does not represent curative therapy." | 1.46 | Clinical Features of β-Thalassemia and Sickle Cell Disease. ( McGann, PT; Nero, AC; Ware, RE, 2017) |
| "In this cross-sectional study, 100 β-thalassemia intermedia patients who were taking HU with a dose of 8 to 15 mg/kg body weight per day for a period of at least 6 months were randomly selected between February 2013 and October 2014 in southern Iran." | 1.46 | Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia. ( Ebrahimi, A; Haghpanah, S; Heidari, G; Karimi, M; Khavari, M; Miri, HR; Moghadam, M; Rezaei, N; Vazin, A; Zarei, T, 2017) |
| "We described four cases of beta thalassemia with EMH who were treated with HU as a monotherapy." | 1.42 | Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. ( Cohan, N; Karimi, M; Pishdad, P, 2015) |
| "In the present study, 51 β-thalassemia intermediate patients were studied." | 1.42 | Role of XmnIgG Polymorphism in Hydroxyurea Treatment and Fetal Hemoglobin Level at Isfahanian Intermediate β-Thalassemia Patients. ( Ghasemi, T; Motovali-Bashi, M, 2015) |
| "Hydroxyurea was discontinued before a planned pregnancy and during gestation and lactation periods." | 1.40 | Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. ( Karami, H; Kosaryan, M; Yaghobi, N; Zafari, M, 2014) |
| "This study included; 32 β-thalassemia major (β-TM) patients aged 14." | 1.40 | Serum angiogenin level in sickle cell disease and beta thalassemia patients. ( Abdelmaksoud, AA; Bebawy, EK; Matter, RM; Shams, MA, 2014) |
| "Clinical severity of thalassemia intermedia increases with age, with more severe anemia and more frequent complications such as extramedullary hematopoiesis and iron overload mainly related to increased intestinal absorption." | 1.40 | [Current management of thalassemia intermedia]. ( Thuret, I, 2014) |
| "For this purpose, we genotyped β-thalassemia intermedia and major patients and healthy controls, as well as a cohort of compound heterozygous sickle cell disease/β-thalassemia patients receiving HU as HbF augmentation treatment." | 1.39 | Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy. ( Bartsakoulia, M; Borg, J; Felice, AE; Georgitsi, M; Giannakopoulou, O; Giannopoulou, E; Kourakli, A; Lambropoulou, P; Paizi, A; Papachatzopoulou, A; Patrinos, GP; Pavlovic, S; Philipsen, S; Poulas, K; Radmilovic, M; Stavrou, EF; Stojiljkovic-Petrovic, M; Tafrali, C; Zukic, B, 2013) |
| "Stroke is a common cause of morbidity and mortality in sickle cell disease (SCD) and silent cerebral infarction is the most common form of neurologic injury." | 1.39 | Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013) |
| "Hydroxyurea treatment increases fetal γ-globin (fetal hemoglobin, HbF, α2γ2) expression in postnatal life substituting for the missing adult β-globin and is, therefore, an attractive therapeutic approach." | 1.39 | Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. ( Azarkeivan, A; Esteghamat, F; Grosveld, F; Hou, J; Kia, SK; Najmabadi, H; Philipsen, S; Pourfarzad, F; van Ijcken, W; von Lindern, M, 2013) |
| "Moreover, genotype analysis of β-thalassemia major and intermedia patients and an independent cohort of β-thalassemia/SCD compound heterozygous patients that do or do not respond to HU treatment showed that the homozygous mutant state of a tagSNP in the KLF10 3'UTR is not present in β-thalassemia intermedia patients and is underrepresented in β-thalassemia/SCD compound heterozygous patients that respond well to HU treatment." | 1.38 | KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. ( Bartsakoulia, M; Borg, J; Christou, S; Felice, AE; Georgitsi, M; Grosveld, FG; Hou, J; Karkabouna, S; Kleanthous, M; Kourakli, A; Lappa-Manakou, C; Lederer, C; Ozgur, Z; Papachatzopoulou, A; Patrinos, GP; Philipsen, S; Phylactides, M; Stavrou, EF; Tafrali, C; van Ijcken, W; von Lindern, M, 2012) |
| "In treated hydroxyurea group, 11." | 1.37 | Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study. ( Amoozgar, H; Cheriki, S; Farhani, N; Karimi, M; Khodadadi, N, 2011) |
| "Eight patients could be reclassified as thalassemia intermedia on follow up." | 1.36 | Evaluation of the genetic basis of phenotypic heterogeneity in north Indian patients with thalassemia major. ( Ahluwalia, J; Bansal, D; Das, R; Kaur, J; Marwaha, RK; Panigrahi, I; Sharma, N; Trehan, A, 2010) |
| "The aim of this study was to evaluate the tolerance and adverse effects of hydroxyurea (HU) in thalassemia intermedia (TI) patients who had been treated by HU for a period of 10 years." | 1.36 | Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience. ( Cohan, N; Falahi, MJ; Haghpanah, S; Karimi, M; Moosavizadeh, K; Mousavizadeh, K, 2010) |
| "Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public health problems." | 1.35 | Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. ( Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D, 2008) |
| "Hydroxyurea (HU) has been known to cause induction of fetal hemoglobin (HbF), but the efficacy of this treatment in beta-thalassemia patients is still unclear." | 1.35 | Hematologic response to hydroxyurea therapy in children with beta-thalassemia major. ( Kvezereli-Kopadze, A; Kvezereli-Kopadze, M; Mestiashvili, I; Mtvarelidze, Z, 2008) |
| "Hydroxyurea treatment was initiated in 9 patients with thalassemia intermedia (TI) and 45 with thalassemia major (TM)." | 1.34 | Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. ( Abad, MT; Bradai, M; de Montalembert, M; Dechartres, A; Landais, P; Pissard, S; Ribeil, JA, 2007) |
| "The EMH-related pleural effusion is rarely referred to in the literature of thalassemia." | 1.33 | Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia. ( Aessopos, A; Farmakis, D; Kati, M; Moyssakis, I; Polonifi, K; Tassiopoulos, S; Tsironi, M, 2006) |
| "Hydroxyurea (HU) has been shown to reduce the frequency of vaso-occlusive manifestations in both adults and children with sickle cell disease (SCD), and the induction of hemoglobin F (HbF) is thought to be the underlying mechanism responsible for clinical improvement in some patients." | 1.32 | The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. ( Gumruk, F; Gurgey, A; Koc, A, 2003) |
| "Hydroxyurea (HU) has recently been used successfully in TM to control ineffective erythropoiesis." | 1.32 | The bone density of thalassemic patients of Boo Ali Sina Hospital, Sari, Iran in 2002 does hydroxyurea help? ( Kosaryan, M; Shahi, VK; Zadeh, MF, 2004) |
| "Hydroxyurea therapy was initiated to increase the efficacy of erythropoiesis, thereby reducing the required transfusion volume but suppressing concomitantly further expansion of extramedullary hematopoiesis, and finally leading to a reduction of transfusional iron load." | 1.31 | Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. ( Cario, H; Debatin, KM; Kohne, E; Wegener, M, 2002) |
| "Hydroxyurea (HU) is an oral drug that ameliorates the clinical course of sickle cell anemia by increasing the levels of fetal hemoglobin and decreasing the adhesion of red cells to endothelium." | 1.31 | Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea. ( Menegas, D; Moschovi, M; Nicolaidou, P; Nikolaidou, P; Psychou, F; Tsangaris, GT; Tzortzatou-Stathopoulou, F, 2001) |
| "Based on the molecular analysis of beta-thalassemia intermedia, beta-thalassemia homozygotes or compound heterozygotes combined with alpha-thalassemia, as well as the conjunctive abnormalities of beta-thalassemia heterozygote with triplicated haplotype of alpha-globin genes, were the most common cause of thalassemia intermedia in China." | 1.31 | The studies of hemoglobinopathies and thalassemia in China--the experiences in Shanghai Institute of Medical Genetics. ( Huang, S; Zeng, Y, 2001) |
| " A reduced dosage of hydroxyurea alternating with erythropoietin may prove less myelotoxic than hydroxyurea given daily or in pulsed-dose regimens." | 1.29 | Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. ( Dover, GJ; Nienhuis, AW; Noguchi, CT; Rodgers, GP; Schechter, AN; Uyesaka, N, 1993) |
| "Treatment with hydroxyurea induced statistically significant increases in the total hemoglobin concentration, mean corpuscular volume, and percentage of hemoglobin F, and a decrease in the serum concentration of bilirubin." | 1.29 | Hydroxyurea therapy in children severely affected with sickle cell disease. ( Brown, ER; Hillery, CA; Labotka, RJ; Misiewicz, V; Scott, JP, 1996) |
| "As concerns sickle cell anemia, we have underlined some particular aspects of the clinical expression of the disease." | 1.29 | [Study of hemoglobinopathies found in Belgium]. ( Fondu, P, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (16.08) | 18.2507 |
| 2000's | 55 (27.64) | 29.6817 |
| 2010's | 82 (41.21) | 24.3611 |
| 2020's | 30 (15.08) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, ZS | 2 |
| Yeh, TK | 1 |
| Chou, YC | 2 |
| Hsu, T | 1 |
| Lu, CT | 1 |
| Kung, FC | 1 |
| Hsieh, MY | 1 |
| Lin, CH | 1 |
| Chen, CT | 1 |
| James Shen, CK | 1 |
| Jiaang, WT | 1 |
| Patrinos, GP | 9 |
| Chui, DHK | 1 |
| Hardison, RC | 1 |
| Steinberg, MH | 4 |
| Yurtsever, N | 1 |
| Nandi, V | 1 |
| Ziemba, Y | 1 |
| Shi, PA | 1 |
| Constantinou, V | 2 |
| Papayanni, PG | 1 |
| Mallouri, D | 1 |
| Batsis, I | 2 |
| Bouinta, A | 2 |
| Papadopoulou, D | 1 |
| Papadimitriou, V | 1 |
| Kammenou, M | 1 |
| Pantelidou, D | 1 |
| Sotiropoulos, D | 1 |
| Sakellari, I | 1 |
| Anagnostopoulos, A | 2 |
| Yannaki, E | 3 |
| Yasara, N | 2 |
| Wickramarathne, N | 2 |
| Mettananda, C | 2 |
| Silva, I | 1 |
| Hameed, N | 1 |
| Attanayaka, K | 1 |
| Rodrigo, R | 1 |
| Wickramasinghe, N | 1 |
| Perera, L | 1 |
| Manamperi, A | 2 |
| Premawardhena, A | 2 |
| Mettananda, S | 3 |
| Khan, MBN | 2 |
| Iftikhar, F | 2 |
| Ali, M | 2 |
| Danish, A | 2 |
| Shamsi, T | 3 |
| Musharraf, SG | 7 |
| Siddiqui, AJ | 6 |
| Ricchi, P | 1 |
| Meloni, A | 1 |
| Rigano, P | 7 |
| Pistoia, L | 1 |
| Spasiano, A | 1 |
| Allò, M | 1 |
| Messina, G | 1 |
| Quarta, A | 1 |
| Rosso, R | 1 |
| Quota, A | 1 |
| Filosa, A | 1 |
| Maggio, A | 8 |
| Pepe, A | 1 |
| Ansari, SH | 12 |
| Ansari, I | 1 |
| Wasim, M | 1 |
| Sattar, A | 1 |
| Khawaja, S | 1 |
| Zohaib, M | 4 |
| Hussain, Z | 2 |
| Adil, SO | 2 |
| Ansari, AH | 1 |
| Ansari, UH | 1 |
| Farooq, F | 1 |
| Masqati, NU | 1 |
| Parsasefat, M | 1 |
| Safarpour, H | 1 |
| Nomiri, S | 1 |
| Miri-Moghaddam, E | 1 |
| Khan, T | 1 |
| Siriworadetkun, S | 1 |
| Thiengtavor, C | 1 |
| Thubthed, R | 1 |
| Paiboonsukwong, K | 1 |
| Fucharoen, S | 5 |
| Pattanapanyasat, K | 1 |
| Vadolas, J | 1 |
| Svasti, S | 1 |
| Chaichompoo, P | 1 |
| Lad, H | 1 |
| Naskar, S | 1 |
| Punyasri Pasupuleti, SKDB | 1 |
| Nahrel, R | 1 |
| Sihare, P | 1 |
| Chandak, GR | 1 |
| Patra, PK | 1 |
| Kumari, S | 1 |
| Khan, F | 2 |
| Adil, N | 1 |
| Uddin, J | 1 |
| Asmari, M | 1 |
| Foong, WC | 2 |
| Loh, CK | 2 |
| Ho, JJ | 2 |
| Lau, DS | 1 |
| Ali, Z | 1 |
| Ismail, M | 1 |
| Rehman, IU | 1 |
| Rani, GF | 1 |
| Khan, MTM | 1 |
| Ataga, KI | 2 |
| Wichlan, D | 1 |
| Elsherif, L | 1 |
| Derebail, VK | 1 |
| Wogu, AF | 1 |
| Maitra, P | 1 |
| Cai, J | 1 |
| Caughey, MC | 1 |
| Pollock, DM | 1 |
| Pollock, JS | 1 |
| Archer, DR | 1 |
| Hinderliter, AL | 1 |
| Lim, SH | 1 |
| Dutta, D | 1 |
| Moore, J | 1 |
| Lal, A | 1 |
| Bansal, D | 2 |
| Shah, S | 1 |
| Sheth, R | 1 |
| Shah, K | 1 |
| Patel, K | 1 |
| Ali, A | 1 |
| Iqbal, A | 3 |
| Al-Nood, HA | 1 |
| Al-Nood, RM | 1 |
| Ghanem, NS | 1 |
| Al-Hadi, AM | 1 |
| Ali, K | 1 |
| Al-Quteimat, O | 1 |
| Naseem, R | 1 |
| Malhi, SM | 1 |
| Wajdi, M | 1 |
| Jahan, N | 1 |
| Shamsi, TS | 8 |
| Li, L | 1 |
| Sun, ZQ | 1 |
| Srivastava, K | 1 |
| Albasri, J | 1 |
| Alsuhaibani, OM | 1 |
| Aljasem, HA | 1 |
| Bueno, MU | 1 |
| Antonacci, T | 1 |
| Branch, DR | 1 |
| Denomme, GA | 1 |
| Flegel, WA | 1 |
| Jain, M | 1 |
| Chakrabarti, P | 2 |
| Dolai, TK | 1 |
| Ghosh, P | 1 |
| Mandal, PK | 1 |
| Baul, SN | 1 |
| De, R | 1 |
| Parveen, S | 2 |
| Kaleem, B | 1 |
| Qamar, H | 1 |
| Adil, O | 1 |
| Khan, MT | 2 |
| Bhurani, D | 1 |
| Kapoor, J | 1 |
| Yadav, N | 1 |
| Khushoo, V | 1 |
| Agrawal, N | 1 |
| Ahmed, R | 1 |
| Arora, JS | 1 |
| Mehta, P | 1 |
| Grech, L | 1 |
| Sultana, J | 1 |
| Borg, K | 1 |
| Borg, J | 5 |
| Bhasin, N | 1 |
| Price, N | 1 |
| Desoky, SM | 1 |
| Karimi, M | 13 |
| Zarei, T | 2 |
| Bahmanimehr, A | 1 |
| Aramesh, A | 1 |
| Daryanoush, S | 1 |
| Haghpanah, S | 8 |
| Algiraigri, AH | 3 |
| Wright, NAM | 2 |
| Paolucci, EO | 2 |
| Kassam, A | 3 |
| Maroofi, N | 1 |
| Azarkeivan, A | 4 |
| Banihashemi, S | 1 |
| Mohammadparast, S | 2 |
| Aghajanirefah, A | 1 |
| Banan, M | 3 |
| Hojjati, MT | 1 |
| Pourfathollah, AA | 1 |
| Amirizadeh, N | 1 |
| Chondrou, V | 3 |
| Kolovos, P | 1 |
| Sgourou, A | 5 |
| Kourakli, A | 6 |
| Pavlidaki, A | 1 |
| Kastrinou, V | 1 |
| John, A | 3 |
| Symeonidis, A | 4 |
| Ali, BR | 3 |
| Papachatzopoulou, A | 8 |
| Katsila, T | 4 |
| McGann, PT | 1 |
| Nero, AC | 1 |
| Ware, RE | 1 |
| Cui, S | 1 |
| Engel, JD | 1 |
| Ravangard, R | 1 |
| Mirzaei, Z | 1 |
| Keshavarz, K | 1 |
| Chatterjee, T | 1 |
| Chakravarty, A | 1 |
| Chakravarty, S | 1 |
| Di Maggio, R | 1 |
| Hsieh, MM | 1 |
| Zhao, X | 1 |
| Calvaruso, G | 2 |
| Renda, D | 3 |
| Tisdale, JF | 1 |
| Niihara, Y | 1 |
| Miller, ST | 1 |
| Kanter, J | 1 |
| Lanzkron, S | 1 |
| Smith, WR | 1 |
| Hsu, LL | 1 |
| Gordeuk, VR | 1 |
| Viswanathan, K | 1 |
| Sarnaik, S | 1 |
| Osunkwo, I | 1 |
| Guillaume, E | 1 |
| Sadanandan, S | 1 |
| Sieger, L | 1 |
| Lasky, JL | 1 |
| Panosyan, EH | 1 |
| Blake, OA | 1 |
| New, TN | 1 |
| Bellevue, R | 1 |
| Tran, LT | 1 |
| Razon, RL | 1 |
| Stark, CW | 1 |
| Neumayr, LD | 1 |
| Vichinsky, EP | 5 |
| Zubarev, RA | 1 |
| Zarina, S | 2 |
| Stavrou, EF | 4 |
| Markopoulos, G | 1 |
| Kouraklis-Symeonidis, A | 1 |
| Fotopoulos, V | 1 |
| Vlachaki, E | 2 |
| Chalkia, P | 2 |
| Khan, IA | 1 |
| Biswas, S | 2 |
| Nag, A | 1 |
| Ghosh, K | 8 |
| Ray, R | 2 |
| Roy, K | 2 |
| Bandyopadhyay, A | 2 |
| Bhattacharyya, M | 2 |
| Khalid, A | 1 |
| Huang, JH | 1 |
| Lassi, ZS | 1 |
| Khowaja, SM | 1 |
| Atwa, ZT | 1 |
| Wahed, WYA | 1 |
| Kolliopoulou, A | 1 |
| Siamoglou, S | 2 |
| Theodoridou, S | 1 |
| Mannan, J | 1 |
| Naveed, M | 1 |
| Ahdi, SG | 1 |
| Racho, RG | 1 |
| Krishna, M | 1 |
| Canabal, JM | 1 |
| Keaveny, AP | 1 |
| Tafrali, C | 3 |
| Paizi, A | 1 |
| Radmilovic, M | 1 |
| Bartsakoulia, M | 3 |
| Giannopoulou, E | 2 |
| Giannakopoulou, O | 1 |
| Stojiljkovic-Petrovic, M | 1 |
| Zukic, B | 1 |
| Poulas, K | 2 |
| Lambropoulou, P | 1 |
| Felice, AE | 3 |
| Philipsen, S | 3 |
| Pavlovic, S | 1 |
| Georgitsi, M | 3 |
| Keikhaei, B | 1 |
| Mohseni, AR | 1 |
| Norouzirad, R | 1 |
| Alinejadi, M | 1 |
| Ghanbari, S | 1 |
| Shiravi, F | 1 |
| Solgi, G | 1 |
| Ronchi, A | 2 |
| Ottolenghi, S | 2 |
| Breda, L | 1 |
| Rivella, S | 1 |
| Zuccato, C | 1 |
| Gambari, R | 1 |
| Pecoraro, A | 5 |
| Iannello, S | 1 |
| Kutlar, A | 1 |
| Reid, ME | 1 |
| Inati, A | 1 |
| Taher, AT | 2 |
| Abboud, MR | 1 |
| El-Beshlawy, A | 2 |
| Buchanan, GR | 2 |
| Smith, H | 1 |
| Perrine, SP | 2 |
| Ghalie, RG | 1 |
| Ansari, S | 1 |
| Elalfy, MS | 1 |
| Adly, AA | 3 |
| Ismail, EA | 3 |
| Elhenawy, YI | 1 |
| Elghamry, IR | 1 |
| Troia, A | 4 |
| Calzolari, R | 5 |
| Scazzone, C | 2 |
| Di Marzo, R | 4 |
| Bohara, VV | 1 |
| Ray, S | 1 |
| Ray, SS | 1 |
| Nath, UK | 1 |
| Chaudhuri, U | 1 |
| Kosaryan, M | 3 |
| Karami, H | 1 |
| Zafari, M | 2 |
| Yaghobi, N | 1 |
| Matter, RM | 1 |
| Abdelmaksoud, AA | 1 |
| Shams, MA | 1 |
| Bebawy, EK | 1 |
| Cohan, N | 3 |
| Pishdad, P | 2 |
| Alipur, A | 1 |
| Hedayatizadeh-Omran, A | 1 |
| El-Ghamrawy, M | 1 |
| EL-Ela, MA | 1 |
| Said, F | 1 |
| Adolf, S | 1 |
| Abdel-Razek, AR | 1 |
| Magdy, RI | 1 |
| Abdel-Salam, A | 1 |
| Tantawy, AA | 2 |
| Darwish, YW | 1 |
| Ali Zedan, M | 1 |
| Boonyawat, K | 1 |
| Wongwaisayawan, S | 1 |
| Nitiyanant, P | 1 |
| Atichartakarn, V | 1 |
| Gravia, A | 1 |
| Papantoni, I | 1 |
| Thuret, I | 1 |
| Wong, TE | 1 |
| Brandow, AM | 1 |
| Lim, W | 1 |
| Lottenberg, R | 1 |
| Adekile, A | 1 |
| Menzel, S | 1 |
| Gupta, R | 1 |
| Al-Sharida, S | 1 |
| Farag, A | 1 |
| Haider, M | 1 |
| Akbulut, N | 1 |
| Mustafa, N | 1 |
| Thein, SL | 2 |
| Chen, RL | 1 |
| Song, JS | 1 |
| Chao, YS | 1 |
| Shen, CK | 1 |
| Martorana, A | 1 |
| Sacco, M | 1 |
| Motovali-Bashi, M | 1 |
| Ghasemi, T | 1 |
| Durlak, M | 1 |
| Fugazza, C | 1 |
| Elangovan, S | 1 |
| Marini, MG | 1 |
| Marongiu, MF | 1 |
| Moi, P | 1 |
| Fraietta, I | 1 |
| Cappella, P | 1 |
| Barbarani, G | 1 |
| Font-Monclus, I | 1 |
| Mauri, M | 1 |
| Gasparri, F | 1 |
| Hashim, Z | 1 |
| Chalikiopoulou, C | 1 |
| Tavianatou, AG | 1 |
| Kelepouri, D | 1 |
| Chrysanthakopoulou, M | 1 |
| Kanelaki, VK | 1 |
| Mourdoukoutas, E | 1 |
| Huang, L | 1 |
| Yao, HX | 1 |
| Italia, K | 1 |
| Chandrakala, S | 2 |
| Colah, R | 1 |
| Viprakasit, V | 1 |
| Sripichai, O | 1 |
| Fisher, CA | 1 |
| Sloane-Stanley, JA | 1 |
| Taylor, S | 1 |
| Oppermann, U | 1 |
| Gibbons, RJ | 1 |
| Higgs, DR | 1 |
| Moghadam, M | 1 |
| Ebrahimi, A | 1 |
| Rezaei, N | 1 |
| Heidari, G | 1 |
| Vazin, A | 1 |
| Khavari, M | 1 |
| Miri, HR | 1 |
| Singer, ST | 3 |
| Larkin, S | 1 |
| Olivieri, N | 1 |
| Sweeters, N | 3 |
| Kuypers, FA | 3 |
| Meo, A | 1 |
| Cassinerio, E | 1 |
| Castelli, R | 1 |
| Bignamini, D | 1 |
| Perego, L | 1 |
| Cappellini, MD | 2 |
| Borzouee, M | 2 |
| Mehrabani, A | 1 |
| Fathallah, H | 1 |
| Zamani, F | 1 |
| Shakeri, R | 1 |
| Eslami, SM | 1 |
| Razavi, SM | 1 |
| Basi, A | 1 |
| Italia, KY | 3 |
| Jijina, FJ | 1 |
| Merchant, R | 2 |
| Panjwani, S | 2 |
| Nadkarni, AH | 3 |
| Sawant, PM | 2 |
| Nair, SB | 2 |
| Colah, RB | 3 |
| Ileri, T | 1 |
| Azik, F | 1 |
| Ertem, M | 1 |
| Uysal, Z | 1 |
| Gozdasoglu, S | 1 |
| Gaudreau, PO | 1 |
| Weng, X | 1 |
| Cournoyer, G | 1 |
| Robin, L | 1 |
| Gagnon, C | 1 |
| Soulières, D | 1 |
| Jijina, FF | 2 |
| Sawant, P | 1 |
| Mohammadi, F | 1 |
| Behmanesh, F | 1 |
| Samani, SM | 1 |
| Amoozgar, H | 2 |
| Ehsani, MA | 1 |
| Hedayati-Asl, AA | 1 |
| Bagheri, A | 1 |
| Zeinali, S | 1 |
| Rashidi, A | 1 |
| Sharma, N | 1 |
| Das, R | 1 |
| Kaur, J | 1 |
| Ahluwalia, J | 1 |
| Trehan, A | 1 |
| Panigrahi, I | 2 |
| Marwaha, RK | 1 |
| Mousavizadeh, K | 1 |
| Moosavizadeh, K | 1 |
| Falahi, MJ | 1 |
| Stamatoyannopoulos, G | 2 |
| Mannucci, PM | 1 |
| Acuto, S | 2 |
| Pantalone, GR | 1 |
| Lopes da Silva, R | 1 |
| Silva, M | 1 |
| Farhani, N | 1 |
| Khodadadi, N | 1 |
| Cheriki, S | 1 |
| Ashraf, M | 2 |
| Perveen, K | 3 |
| Farzana, T | 3 |
| Bohray, M | 1 |
| Erum, S | 2 |
| Mehboob, T | 3 |
| Mokhtar, GM | 1 |
| Papayannopoulou, T | 1 |
| Jonlin, E | 1 |
| Zervou, F | 1 |
| Karponi, G | 1 |
| Xagorari, A | 1 |
| Becker, P | 1 |
| Psatha, N | 1 |
| Kaloyannidis, P | 1 |
| Tahynopoulou, V | 1 |
| Kotta, K | 1 |
| Athanassiadou, A | 1 |
| Fassas, A | 1 |
| Farhadi, A | 1 |
| Yavarian, M | 2 |
| Zekavat, OR | 1 |
| Javad, P | 1 |
| Karamizadeh, Z | 1 |
| Bayat, H | 1 |
| Kamali, K | 1 |
| Farashi, S | 1 |
| Bayat, N | 1 |
| Khani, MH | 1 |
| Neishabury, M | 1 |
| Najmabadi, H | 2 |
| Bagheri, MH | 1 |
| Bordbar, MR | 1 |
| Rachmilewitz, EA | 1 |
| Phylactides, M | 1 |
| Lederer, C | 1 |
| Christou, S | 1 |
| Hou, J | 2 |
| Karkabouna, S | 1 |
| Lappa-Manakou, C | 1 |
| Ozgur, Z | 1 |
| van Ijcken, W | 2 |
| von Lindern, M | 2 |
| Grosveld, FG | 1 |
| Kleanthous, M | 1 |
| Pourfarzad, F | 1 |
| Kia, SK | 1 |
| Esteghamat, F | 1 |
| Grosveld, F | 1 |
| Musallam, KM | 1 |
| Sankaran, VG | 1 |
| Munzir, S | 1 |
| Moinuddin, M | 1 |
| Cario, H | 1 |
| Wegener, M | 1 |
| Debatin, KM | 1 |
| Kohne, E | 1 |
| Ajanta, H | 1 |
| Chakraborty, S | 1 |
| Madhusnata, D | 1 |
| Bhattacharya, DK | 1 |
| Manisha, D | 1 |
| Kohli-Kumar, M | 1 |
| Marandi, H | 1 |
| Keller, MA | 1 |
| Guertin, K | 1 |
| Hvizdala, E | 1 |
| Halsey, C | 1 |
| Roberts, IA | 1 |
| Knox-Macaulay, H | 1 |
| Ayyaril, M | 1 |
| Nusrat, N | 1 |
| Daar, A | 1 |
| de Paula, EV | 1 |
| Lima, CS | 2 |
| Arruda, VR | 2 |
| Alberto, FL | 1 |
| Saad, ST | 3 |
| Costa, FF | 3 |
| Bradai, M | 2 |
| Abad, MT | 2 |
| Pissard, S | 2 |
| Lamraoui, F | 1 |
| Skopinski, L | 1 |
| de Montalembert, M | 2 |
| Amoyal, I | 1 |
| Goldfarb, A | 1 |
| Fibach, E | 4 |
| Koc, A | 1 |
| Gumruk, F | 1 |
| Gurgey, A | 1 |
| Alebouyeh, M | 1 |
| Moussavi, F | 1 |
| Haddad-Deylami, H | 1 |
| Vossough, P | 1 |
| Cao, H | 1 |
| Bakker, E | 1 |
| Harteveld, CL | 1 |
| Giordano, PC | 1 |
| Dixit, A | 2 |
| Chatterjee, TC | 1 |
| Mishra, P | 1 |
| Choudhry, DR | 1 |
| Mahapatra, M | 2 |
| Tyagi, S | 1 |
| Kabra, M | 2 |
| Saxena, R | 2 |
| Choudhry, VP | 2 |
| Arora, S | 1 |
| Olivieri, NF | 7 |
| Weatherall, DJ | 4 |
| Mignacca, R | 2 |
| Coates, TD | 2 |
| Davies, S | 2 |
| Dincer, AP | 1 |
| Subramanian, S | 1 |
| Goksel, M | 1 |
| Watanapokasin, Y | 1 |
| Chuncharunee, S | 1 |
| Sanmund, D | 2 |
| Kongnium, W | 1 |
| Winichagoon, P | 3 |
| Rodgers, GP | 11 |
| Watanapokasin, R | 1 |
| Muta, K | 1 |
| Taher, A | 2 |
| Sheikh-Taha, M | 2 |
| Zadeh, MF | 1 |
| Shahi, VK | 1 |
| Gamberini, MR | 2 |
| Fortini, M | 2 |
| De Sanctis, V | 2 |
| Aessopos, A | 1 |
| Tassiopoulos, S | 1 |
| Farmakis, D | 1 |
| Moyssakis, I | 1 |
| Kati, M | 1 |
| Polonifi, K | 1 |
| Tsironi, M | 1 |
| Koussa, S | 1 |
| Quinn, CT | 1 |
| Shull, EP | 1 |
| Ahmad, N | 1 |
| Lee, NJ | 1 |
| Rogers, ZR | 1 |
| Pizzuto, M | 1 |
| Cassar, W | 1 |
| Galdies, R | 1 |
| Wettinger, SB | 1 |
| Pulis, S | 1 |
| Hunter, GJ | 1 |
| Caruana, MR | 1 |
| Farrugia, M | 1 |
| Scerri, CA | 1 |
| Voskaridou, E | 6 |
| Tsetsos, G | 1 |
| Tsoutsias, A | 1 |
| Spyropoulou, E | 1 |
| Christoulas, D | 1 |
| Terpos, E | 2 |
| Dechartres, A | 1 |
| Ribeil, JA | 1 |
| Landais, P | 1 |
| Siddiqui, FJ | 1 |
| Irfan, M | 1 |
| Panjwani, VK | 1 |
| Yousuf, A | 1 |
| Moutouh-de Parseval, LA | 1 |
| Verhelle, D | 1 |
| Glezer, E | 1 |
| Jensen-Pergakes, K | 1 |
| Ferguson, GD | 1 |
| Corral, LG | 1 |
| Morris, CL | 1 |
| Muller, G | 1 |
| Brady, H | 1 |
| Chan, K | 1 |
| Koren, A | 1 |
| Levin, C | 1 |
| Dgany, O | 1 |
| Kransnov, T | 1 |
| Elhasid, R | 1 |
| Zalman, L | 1 |
| Palmor, H | 1 |
| Tamary, H | 1 |
| Mtvarelidze, Z | 1 |
| Kvezereli-Kopadze, A | 1 |
| Kvezereli-Kopadze, M | 1 |
| Mestiashvili, I | 1 |
| Borruso, V | 1 |
| el-Hazmi, MA | 1 |
| al-Momen, A | 1 |
| Kandaswamy, S | 1 |
| Huraib, S | 1 |
| Harakati, M | 1 |
| al-Mohareb, F | 1 |
| Warsy, AS | 1 |
| Hajjar, FM | 1 |
| Pearson, HA | 2 |
| Kalotychou, V | 3 |
| Loukopoulos, D | 5 |
| Kollia, P | 1 |
| Schechter, AN | 6 |
| Noguchi, CT | 3 |
| Zeng, YT | 2 |
| Huang, SZ | 2 |
| Ren, ZR | 2 |
| Lu, ZH | 1 |
| Zeng, FY | 2 |
| Zauber, NP | 1 |
| Vlad, LD | 1 |
| Bunn, HF | 1 |
| Dover, GJ | 2 |
| Uyesaka, N | 1 |
| Nienhuis, AW | 1 |
| Burke, LP | 1 |
| Prasanna, P | 1 |
| Samid, D | 1 |
| Chen, MJ | 1 |
| Xu, HP | 1 |
| Sauvage, C | 1 |
| Rouyer-Fessard, P | 2 |
| Beuzard, Y | 2 |
| de Franceschi, L | 1 |
| Alper, SL | 1 |
| Jouault, H | 1 |
| Brugnara, C | 1 |
| Siritanaratkul, N | 1 |
| Chowthaworn, J | 1 |
| Siriboon, W | 1 |
| Muangsup, W | 1 |
| Chaicharoen, S | 1 |
| Poolsup, N | 1 |
| Chindavijak, B | 1 |
| Pootrakul, P | 1 |
| Piankijagum, A | 1 |
| Scott, JP | 1 |
| Hillery, CA | 1 |
| Brown, ER | 1 |
| Misiewicz, V | 1 |
| Labotka, RJ | 1 |
| Fondu, P | 1 |
| Manfré, L | 1 |
| La Galla, R | 1 |
| Renda, MC | 1 |
| Calabrese, A | 1 |
| Rees, DC | 1 |
| Ginder, GD | 1 |
| Brittenham, GM | 1 |
| Waye, JS | 2 |
| Charache, S | 1 |
| Saxon, BR | 2 |
| Rees, D | 1 |
| Stamoulakatou, A | 2 |
| Papassotiriou, Y | 1 |
| Loutradi, A | 2 |
| Cozma, G | 1 |
| Tsiarta, H | 1 |
| Pavlides, N | 2 |
| Styles, L | 2 |
| Lewis, B | 2 |
| Foote, D | 2 |
| Cuda, L | 1 |
| Konstantopoulos, K | 1 |
| Lymperi, S | 1 |
| Angastiniotis, M | 1 |
| Aristidou, K | 1 |
| Kanakas, A | 1 |
| Yerakaris, M | 1 |
| Eracleous, E | 1 |
| Posporis, T | 1 |
| Hoppe, C | 1 |
| Vichinsky, E | 1 |
| Chiba, K | 1 |
| Kurosawa, M | 1 |
| Kondo, T | 1 |
| Suzuki, S | 1 |
| Musashi, M | 1 |
| Asaka, M | 1 |
| Imamura, M | 1 |
| Hattori, Y | 1 |
| Oba, Y | 1 |
| Cianciulli, P | 1 |
| di Toritto, TC | 1 |
| Sorrentino, F | 1 |
| Sergiacomi, L | 1 |
| Massa, A | 1 |
| Amadori, S | 1 |
| Schina, M | 1 |
| Theodoropoulos, I | 1 |
| Bincoletto, C | 1 |
| Perlingeiro, RC | 1 |
| Queiroz, ML | 1 |
| Saunthararajah, Y | 1 |
| Moschovi, M | 1 |
| Psychou, F | 1 |
| Menegas, D | 1 |
| Tsangaris, GT | 1 |
| Tzortzatou-Stathopoulou, F | 1 |
| Nicolaidou, P | 1 |
| Nikolaidou, P | 1 |
| Zeng, Y | 1 |
| Huang, S | 1 |
| Komninaka, V | 1 |
| Eftyhiadis, E | 1 |
| Mantzourani, M | 1 |
| Papassotiriou, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Combination of Hydroxyurea and Low-dose Thalidomide on Hemoglobin Synthesis in Thalassemia Patients[NCT05132270] | Phase 2/Phase 3 | 135 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014] | Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-08 | Recruiting | ||
| A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA[NCT01179217] | Phase 3 | 230 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Single-center Pilot Study: Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects)[NCT05530239] | 40 participants (Anticipated) | Observational | 2022-10-31 | Not yet recruiting | |||
| A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease[NCT04432623] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2020-10-05 | Recruiting | ||
| Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients[NCT02467257] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease[NCT01322269] | Phase 2 | 52 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Phase 2 Study of Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.[NCT01624038] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2012-06-30 | Not yet recruiting | ||
| A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD[NCT03055247] | Phase 2 | 3 participants (Anticipated) | Interventional | 2015-11-06 | Recruiting | ||
| Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial[NCT02573714] | 160 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118] | 82 participants (Actual) | Observational | 2015-12-31 | Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion) | |||
| A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome[NCT00467610] | Phase 2 | 6 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to lack of efficacy.) | ||
| Effect of Hydroxyurea on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia[NCT00001197] | Phase 2 | 41 participants (Actual) | Interventional | 1984-02-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of emergency room visits or medical facility visits that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of ER visits (Median) |
|---|---|
| L-glutamine | 1 |
| 100% Maltodextrin | 1 |
The number of hospitalizations that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of hospitalizations (Median) |
|---|---|
| L-glutamine | 2 |
| 100% Maltodextrin | 3 |
The number of occurrences of protocol-defined sickle cell crises that occur from Week 0 to Week 48 will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of crises (Median) |
|---|---|
| L-glutamine | 3 |
| 100% Maltodextrin | 4 |
To assess the effect of oral L-glutamine on Vital signs (temperature). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | degree C (Mean) | |||
|---|---|---|---|---|
| Temperature at Baseline | Change in Temperature at Week 4 | Change in Temperature at Week 24 | Change in Temperature at Week 48 | |
| 100% Maltodextrin | 36.83 | -0.02 | 0.03 | 0.05 |
| L-glutamine | 36.85 | -0.06 | -0.05 | -0.09 |
To assess the effect of oral L-glutamine on hematological parameters (hemoglobin), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Hemoglobin at Baseline | Change in Hemoglobin at week 4 | Change in Hemoglobin at Week 24 | Change in Hemoglobin at Week 48 | |
| L-glutamine | 8.82 | 0.04 | -0.17 | -0.12 |
| Placebo | 8.71 | 0.23 | -0.12 | -0.12 |
To assess the effect of oral L-glutamine on hematological parameters (hematocrit), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | % of red blood cells (Mean) | |||
|---|---|---|---|---|
| Hematocrit at Baseline | Change in Hematocrit at Week 4 | Change in Hematocrit Week 24 | Change in Hematocrit at Week 48 | |
| 100% Maltodextrin | 27.53 | 0.75 | -0.15 | 0.11 |
| L-glutamine | 27.67 | 0.16 | -0.26 | 0.16 |
To assess the effect of oral L-glutamine on hematological parameters (reticulocyte count), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | 1000 cells/uL (Mean) | |||
|---|---|---|---|---|
| Reticulocyte (Abs) | Change in Reticulocyte (Abs) at Week 4 | Change in Reticulocyte (Abs) at Week 24 | Change in Reticulocyte (Abs) at Week 48 | |
| 100% Maltodextrin | 295.03 | -23.09 | -1.93 | 26.27 |
| L-glutamine | 283.62 | -9.28 | 7.94 | 50.89 |
To assess the effect of oral L-glutamine on Vital signs (pulse rate). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | bpm (Mean) | |||
|---|---|---|---|---|
| Pulse Rate (bpm) at Baseline | Change in Pulse Rate (bpm) at Week 4 | Change in Pulse Rate (bpm) at Week 24 | Change in Pulse Rate (bpm) at 48 | |
| 100% Maltodextrin | 88.5 | -0.4 | -1.5 | 0.2 |
| L-glutamine | 85.6 | -0.1 | 3.0 | 1.1 |
To assess the effect of oral L-glutamine on Vital signs (respiration). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | breaths/min (Mean) | |||
|---|---|---|---|---|
| Respiration at Baseline | Change in Respiration at Week 4 | Change in Respiration at Week 24 | Change in Respiration at Week 48 | |
| 100% Maltodextrin | 19.1 | -0.2 | -0.6 | -0.6 |
| L-glutamine | 18.9 | -0.2 | -0.7 | -0.7 |
To assess the effect of oral L-glutamine on Vital signs (systolic and diastolic blood pressure). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24, and 48
| Intervention | mm Hg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure at Baseline | Change Systolic blood pressure at Week 4 | Change in Systolic blood pressure at Week 24 | Change in Systolic blood pressure at Week 48 | Diastolic blood pressure at Baseline | Change in Diastolic blood pressure at Week 4 | Change in Diastolic blood pressure at Week 24 | Change in Diastolic blood pressure at Week 48 | |
| 100% Maltodextrin | 114.6 | -0.2 | 0.5 | 2.6 | 66.2 | 0.3 | 0.6 | 2.0 |
| L-glutamine | 111.3 | 0.5 | 1.1 | 2.2 | 64.8 | -0.7 | -0.7 | 0.4 |
(NCT00467610)
Timeframe: At 8 weeks from start of therapy
| Intervention | participants (Number) |
|---|---|
| Group 1 | 1 |
"Hematological improvement (HI)~Major:~HI-Erythroid:>2 g/dL rise in hemoglobin, or transfusion independence HI-Neutrophil: Absolute increase of >500/mm3, or >100% increase HI-Platelet: Absolute increase of >30,000, or transfusion independence~Minor:~HI-Erythroid:1 to 2 g/dL increase in hemoglobin or 50% decrease in transfusion dependence.~HI-P: For patients with pretreatment platelet count < 100,000/mm3, ≥ 50% increase with a net increase > 10,000/mm3 but < 30,000/mm3.~HI-N: For patients with pretreatment ANC < 1500/mm3, ≥ 100% increase, but < 500/mm3 increase." (NCT00467610)
Timeframe: 4 weeks after initiation of treatment with Panhematin
| Intervention | participants (Number) |
|---|---|
| Group 1 | 0 |
"Complete response(CR): <5% blasts in the bone marrow,with normal maturation of all cell lines, Hemoglobin >11 g/dL, neutrophils>1500/mm3 platelets>100,000/mm3.~Partial response (PR): >50% decrease in blasts, or less advanced IPSS than pretreatment value, same hematological parameters as in CR.~Stable disease (SD): No evidence of disease progression in bone marrow, stable peripheral blood counts failure: Increase in bone marrow blast percentage, progression to more advanced IPSS than pretreatment and worsening of cytopenias.~(Cheson, 2000)" (NCT00467610)
Timeframe: After 8 weeks of therapy with panhematin
| Intervention | Participants (Number) |
|---|---|
| Group 1 | 0 |
Number of patients with no adverse events. (NCT00467610)
Timeframe: participants were followed during therapy with panhematin, and up to six months post completion of therapy, average of 8 months.
| Intervention | participants (Number) |
|---|---|
| Group 1 | 6 |
30 reviews available for hydroxyurea and Anemia, Cooley's
| Article | Year |
|---|---|
Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.
Topics: beta-Thalassemia; Blood Transfusion; Fetal Hemoglobin; Humans; Hydroxyurea; Resveratrol | 2023 |
Thalassemia: Common Clinical Queries in Management.
Topics: beta-Thalassemia; Blood Transfusion; Chelation Therapy; Humans; Hydroxyurea; India; Splenectomy; Tha | 2020 |
[Reaserch Advances on Induction of Fetal Hemoglobin (HbF) by Drugs in the Treatment of β-Thalassemia--Review].
Topics: beta-Globins; beta-Thalassemia; Blood Transfusion; Fetal Hemoglobin; Humans; Hydroxyurea | 2020 |
Drug safety in thalassemia: lessons from the present and directions for the future.
Topics: Activin Receptors, Type II; beta-Thalassemia; Hematinics; Humans; Hydroxyurea; Immunoglobulin Fc Fra | 2021 |
Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Humans; Hydroxyurea | 2017 |
Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.
Topics: beta-Thalassemia; Hemoglobin E; Humans; Hydroxyurea; Randomized Controlled Trials as Topic | 2017 |
Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.
Topics: beta-Thalassemia; Female; Humans; Hydroxyurea; Male; Observational Studies as Topic | 2017 |
Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.
Topics: beta-Thalassemia; Blood Transfusion; Hematinics; Humans; Hydroxyurea | 2019 |
The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012.
Topics: beta-Thalassemia; Blood Transfusion; Erythrocyte Indices; Humans; Hydroxyurea; Treatment Outcome | 2014 |
Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Fetal Hemoglobin; Humans; Hydroxyurea; Pharmacogenetics; Poly | 2014 |
Update on the use of hydroxyurea therapy in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Antisickling Agents; beta-Thala | 2014 |
Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.
Topics: beta-Thalassemia; Blood Transfusion; Hematinics; Hemoglobin A; Humans; Hydroxyurea; Randomized Contr | 2016 |
Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches.
Topics: Animals; beta-Thalassemia; Carrier Proteins; Epistasis, Genetic; Fetal Hemoglobin; Gene Editing; Gen | 2016 |
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythropoiesis; Erythropoietin; Fatty Ac | 2008 |
Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review.
Topics: Adult; beta-Thalassemia; Female; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Middle Ag | 2008 |
Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Topics: Adolescent; beta-Globins; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Drug Monitor | 2009 |
Hydroxyurea in the management of thalassemia intermedia.
Topics: Antineoplastic Agents; beta-Thalassemia; Hemoglobins; Humans; Hydroxyurea; Treatment Outcome | 2009 |
Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Clinical Trials as Topic; Genetic Therapy; Granulocyte Colony | 2010 |
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Azacitidine; beta-Thalassemia; DNA Methylation; Fetal Hemo | 2013 |
Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
Topics: Animals; beta-Thalassemia; Enzyme Inhibitors; Humans; Hydroxyurea; Polymorphism, Single Nucleotide; | 2013 |
The role of hydroxyurea in sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cell Communicat | 2003 |
Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.
Topics: Anemia, Sickle Cell; Azacitidine; beta-Thalassemia; Enzyme Inhibitors; Fetal Hemoglobin; Histone Dea | 2004 |
Reactivation of fetal hemoglobin in patients with beta-thalassemia.
Topics: Azacitidine; beta-Thalassemia; Butyrates; Butyric Acid; Erythropoietin; Fetal Hemoglobin; Homozygote | 1996 |
Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Azacitidine; beta-Thalassemia; Eryt | 1996 |
Treatment of sickling disorders.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Component Removal; Blood Transfusi | 1996 |
Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
Topics: Antisickling Agents; beta-Thalassemia; Blood Transfusion; Erythropoietin; Fetal Hemoglobin; Globins; | 1998 |
The therapeutic reactivation of fetal haemoglobin.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Butyrates; Clinical Trials as Topic; Fet | 1998 |
Pharmacological therapy.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Thalassemia; Child; Fatty Acids; Fetal Hemog | 1998 |
Advances in experimental treatment of beta-thalassaemia.
Topics: Azacitidine; beta-Thalassemia; Drug Therapy, Combination; Erythropoietin; Histone Deacetylase Inhibi | 2001 |
Pharmacologic modulation of fetal hemoglobin.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Child, Preschool; Combined Modali | 2001 |
35 trials available for hydroxyurea and Anemia, Cooley's
| Article | Year |
|---|---|
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Double-Blind Method; F | 2022 |
Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study.
Topics: beta-Thalassemia; Ferritins; Humans; Hydroxyurea; Thalidomide; Treatment Outcome; Uric Acid | 2023 |
A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.
Topics: Aged; Albuminuria; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; beta | 2019 |
Safety and effectiveness of thalidomide and hydroxyurea combination in β-thalassaemia intermedia and major: a retrospective pilot study.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; Ret | 2020 |
Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial.
Topics: Adolescent; Adult; beta-Thalassemia; Double-Blind Method; Humans; Hydroxyurea; Quality of Life; Rand | 2020 |
Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea.
Topics: beta-Thalassemia; Female; Fetal Hemoglobin; gamma-Globins; Gene Expression Regulation; Humans; Hydro | 2017 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
Pharmacoproteomics Profiling of Plasma From β-Thalassemia Patients in Response to Hydroxyurea Treatment.
Topics: Antisickling Agents; beta-Thalassemia; Child, Preschool; Female; Humans; Hydroxyurea; Infant; Male; | 2019 |
The impact of illness perception and socio-clinico-demographic factors on perceived quality of life in children and adolescents with thalassemia intermedia.
Topics: Adolescent; Adult; beta-Thalassemia; Case-Control Studies; Child; Child, Preschool; Female; Humans; | 2019 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
Topics: Adolescent; Age Factors; beta-Thalassemia; Blood Transfusion; Child; Drug Therapy, Combination; Eryt | 2013 |
Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Female; Follow-Up Studies; Hemoglobin E; Humans; Hydroxy | 2014 |
[Curative Effects of Hydroxyurea on the Patients with β-thalassaemia Intermadia].
Topics: beta-Thalassemia; Blood Transfusion; Ferritins; Hemoglobins; Humans; Hydroxyurea; Reticulocytes; Tre | 2016 |
Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Female; Fetal Hemoglobin; Gene Express | 2009 |
Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Urea Nitrogen; Carnitine; Child; Child, Preschool; Creati | 2010 |
Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
Topics: Adolescent; Adult; beta-Globins; beta-Thalassemia; Blood Transfusion; Child; Combined Modality Thera | 2010 |
Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cells, Cultured; Drug Administration Schedule; Drug Tolerance; | 2010 |
Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
Topics: Adolescent; beta-Thalassemia; Child; Child, Preschool; Erythrocyte Transfusion; Female; Follow-Up St | 2011 |
Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
Topics: Adult; Antigens, CD34; Benzylamines; beta-Thalassemia; Cyclams; Female; Genetic Therapy; Granulocyte | 2012 |
Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.
Topics: beta-Thalassemia; Child, Preschool; Deoxyribonucleases, Type II Site-Specific; Female; Humans; Hydro | 2013 |
Long-term hydroxyurea therapy in beta-thalassaemia patients.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Blood Cell Count; Clinical Enzyme Tests; Creatine; Erythr | 2003 |
Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Female; Follow-Up Studies; | 2003 |
Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Child, Preschool; Combined Modality Th | 2004 |
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Topics: Adolescent; Adult; Alleles; beta-Thalassemia; Blood Transfusion; Child; Combined Modality Therapy; D | 2004 |
Hydroxyurea in thalassemia intermedia--a promising therapy.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; beta-Thalassemia; Child; Child, Pres | 2005 |
Do alpha deletions influence hydroxyurea response in thalassemia intermedia?
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deoxyribonucleases, Type II Site-Speci | 2005 |
Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Child; Drug Therapy, Combination; Erythrocyte Aging | 2005 |
In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients.
Topics: Adult; beta-Thalassemia; Cells, Cultured; Drug Monitoring; Erythroid Cells; Female; Fetal Hemoglobin | 2005 |
Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
Topics: beta-Thalassemia; Blood Transfusion; Combined Modality Therapy; Drug Therapy, Combination; Erythropo | 2005 |
Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
Topics: Adolescent; Antisickling Agents; beta-Thalassemia; Child; Child, Preschool; Erythrocyte Transfusion; | 2007 |
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combina | 1995 |
Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia.
Topics: Adult; Aged; Anemia, Sickle Cell; beta-Thalassemia; Cell Size; Drug Administration Schedule; Erythro | 1995 |
Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Combined Modality Therapy; Erythrocyte Count | 1996 |
Hydroxyurea therapy in thalassemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Erythropoiesi | 1998 |
Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Topics: Acute Disease; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythr | 2000 |
134 other studies available for hydroxyurea and Anemia, Cooley's
| Article | Year |
|---|---|
Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Thalassemia; Cell Memb | 2021 |
Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Hemoglobinopathies; Humans; Hydroxyurea; Pharmacogenetics | 2021 |
Prognostic factors associated with COVID-19 related severity in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; COVID-19; Female; Genotype; Health Personnel; H | 2021 |
Case study of betibeglogene autotemcel gene therapy in an adult Greek patient with transfusion-dependent β-thalassaemia of a severe genotype.
Topics: Adult; beta-Thalassemia; Genetic Therapy; Genotype; Greece; Humans; Hydroxyurea | 2022 |
XMN polymorphism along with HU administration renders alterations to RBC membrane lipidome in β-thalassemia patients.
Topics: beta-Thalassemia; Chromatography, Liquid; Humans; Hydroxyurea; Lipidomics; Membrane Lipids; Tandem M | 2022 |
The use of hydroxyurea in the real life of MIOT network: an observational study.
Topics: Adult; beta-Thalassemia; Female; Hemoglobins; Humans; Hydroxyurea; Middle Aged; Thalassemia; Young A | 2022 |
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.
Topics: beta-Thalassemia; Blood Transfusion; Child; Combined Modality Therapy; Female; Humans; Hydroxyurea; | 2022 |
Treatment with Hydroxyurea Leads to Fetal Hemoglobin Reactivation through
Topics: Adult; beta-Globins; beta-Thalassemia; Fetal Hemoglobin; gamma-Globins; Humans; Hydroxyurea; RNA-Bin | 2022 |
IVS I-5 (G > C) is associated with changes to the RBC membrane lipidome in response to hydroxyurea treatment in β-thalassemia patients.
Topics: beta-Thalassemia; Humans; Hydroxyurea; Lipidomics; Lipids; Mutation | 2022 |
A comprehensive study of immune function and immunophenotyping of white blood cells from β-thalassaemia/HbE patients on hydroxyurea supports the safety of the drug.
Topics: beta-Thalassemia; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Humans; Hydroxyurea; Immunity | 2023 |
Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Child; Drug-Related Side Effects and Adverse Reactions; Fetal | 2023 |
Metabolomics Study of Serum Samples of β-YAC Transgenic Mice Treated with Tenofovir Disoproxil Fumarate.
Topics: Animals; beta-Thalassemia; Fetal Hemoglobin; Hydroxyurea; Metabolomics; Mice; Mice, Transgenic; Teno | 2022 |
Rifaximin for sickle cell disease.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; beta-Thalassemia; Cellular Se | 2019 |
Profiling of hydroxyurea-treated β-thalassemia/ serum proteome through nano-LC-ESI-MS/ MS in combination with microsol-isoelectric focusing.
Topics: beta-Thalassemia; Biomarkers; Blood Proteins; Chromatography, Liquid; Humans; Hydroxyurea; Isoelectr | 2020 |
Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients.
Topics: Adolescent; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Enzym | 2020 |
Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance.
Topics: Adolescent; Ambulatory Care; Antineoplastic Agents; beta-Thalassemia; Child; Child, Preschool; Femal | 2021 |
SCAR: The high-prevalence antigen 013.008 in the Scianna blood group system.
Topics: Alleles; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Group Antigens; Blood Tra | 2021 |
Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
Topics: Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Child; Female; Hemoglobin E; Hemoglobins; | 2021 |
A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.
Topics: beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Hydroxyurea; Mal | 2022 |
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
Topics: Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Child; Drug Combination | 2021 |
Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Child, Preschool; Humans; Hydroxyurea; Male; Osteonecrosis; T | 2022 |
Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
Topics: Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Female; Humans; Hydroxy | 2021 |
An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients.
Topics: beta-Thalassemia; Carrier Proteins; Cohort Studies; Enhancer Elements, Genetic; Gene Frequency; Geno | 2017 |
Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.
Topics: beta-Thalassemia; Biomarkers, Pharmacological; Computer Simulation; Erythroid Cells; Fetal Hemoglobi | 2017 |
Clinical Features of β-Thalassemia and Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythrocyte Transfusion; Genetic Therapy | 2017 |
Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Globins; beta-Thalassemia; Erythroid Cells; Fe | 2017 |
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Female; Humans; Hydroxyurea; Iran | 2018 |
Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Child, Preschool; Female; Follow-Up | 2018 |
Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Child, Prescho | 2018 |
Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Topics: Anemia, Sickle Cell; beta-Globins; beta-Thalassemia; Carrier Proteins; DNA Methylation; DNA-Binding | 2018 |
Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.
Topics: Antisickling Agents; beta-Thalassemia; Child; Humans; Hydroxyurea; Linoleic Acid; Metabolome | 2018 |
Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Female; Fetal Hemog | 2019 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
Reflection of treatment proficiency of hydroxyurea treated β-thalassemia serum samples through nuclear magnetic resonance based metabonomics.
Topics: Adolescent; beta-Thalassemia; Child; Child, Preschool; Female; Fetal Hemoglobin; Hemoglobins; Humans | 2019 |
Impact of hydroxyurea therapy on serum fatty acids of β-thalassemia patients.
Topics: beta-Thalassemia; Biomarkers; Fatty Acids; Humans; Hydroxyurea | 2018 |
Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Topics: Alleles; beta-Globins; beta-Thalassemia; Biomarkers; Female; Fetal Hemoglobin; Genomics; Genotype; H | 2019 |
Mahidol Scoring for Assessing Various Grades of β Thalassemia Intermedia.
Topics: Antisickling Agents; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Cross-Sectional S | 2019 |
Alpha Globin Gene Mutation: A Major Determinant of Hydroxyurea Response in Transfusion-Dependent HbE-β-Thalassaemia.
Topics: Adolescent; Adult; alpha-Globins; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Fema | 2019 |
Liver Transplantation for Acute Liver Failure Secondary to Acute Sickle Intrahepatic Cholestasis.
Topics: Acute Disease; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Bradycardia; Budd-Chiari | 2020 |
Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
Topics: beta-Thalassemia; Biomarkers, Pharmacological; Gene Expression Regulation; Genetic Association Studi | 2013 |
Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Case-Control Studies; Cytokines; Demography; Female; Humans; | 2013 |
To respond or not to respond to hydroxyurea in thalassemia: a matter of stress adaptation?
Topics: Adaptation, Biological; beta-Thalassemia; Erythroid Precursor Cells; Humans; Hydroxyurea; Stress, Ph | 2013 |
Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.
Topics: Antisickling Agents; Azacitidine; beta-Globins; beta-Thalassemia; Decitabine; Fetal Hemoglobin; Gene | 2013 |
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr | 2013 |
Medical management of beta-thalassaemia without blood transfusion: a myth or a reality?
Topics: beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Enzyme Inhibito | 2013 |
Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Topics: Adult; Aged; Anemia, Sickle Cell; beta-Thalassemia; Erythroid Precursor Cells; Female; Fetal Hemoglo | 2014 |
Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Topics: Adult; Antisickling Agents; beta-Globins; beta-Thalassemia; Blood Cell Count; Blood Transfusion; Ery | 2014 |
Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Topics: Adolescent; Age of Onset; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Case-Control Stu | 2014 |
Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports.
Topics: Adult; Antineoplastic Agents; beta-Thalassemia; Female; Hematopoiesis, Extramedullary; Humans; Hydro | 2015 |
Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Combined Modality Therapy | 2014 |
Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Vessels; Case-Control | 2014 |
Hydroxyurea and colonic ulcers: a case report.
Topics: Adult; beta-Thalassemia; Colonic Diseases; Humans; Hydroxyurea; Male; Nucleic Acid Synthesis Inhibit | 2014 |
[Current management of thalassemia intermedia].
Topics: Allografts; alpha-Thalassemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Combined Moda | 2014 |
Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Child, Prescho | 2015 |
Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
Topics: Adult; Anemia, Sickle Cell; Animals; Antineoplastic Agents; beta-Thalassemia; Blotting, Western; But | 2015 |
Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
Topics: Adolescent; Adult; Aged; alpha-Globins; Anemia, Sickle Cell; beta-Globins; beta-Thalassemia; Cells, | 2015 |
Role of XmnIgG Polymorphism in Hydroxyurea Treatment and Fetal Hemoglobin Level at Isfahanian Intermediate β-Thalassemia Patients.
Topics: Adolescent; Adult; beta-Thalassemia; Deoxyribonucleases, Type II Site-Specific; Female; Fetal Hemogl | 2015 |
A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds.
Topics: Anemia, Sickle Cell; beta-Globins; beta-Thalassemia; Butyric Acid; Fetal Hemoglobin; gamma-Globins; | 2015 |
Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy in β-Thalassemia Patients.
Topics: Antioxidants; Aryldialkylphosphatase; beta-Thalassemia; Biomarkers; Child; Enzyme Activation; Female | 2016 |
Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Argininosuccinate Synthase; beta-Thalassemia; Case-Control | 2016 |
Can hydroxyurea serve as a free radical scavenger and reduce iron overload in β-thalassemia patients?
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Female; Free Radical Scavengers; Human | 2016 |
Selective silencing of α-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of β-thalassemia.
Topics: alpha-Globins; Antigens, CD34; beta-Thalassemia; Butyric Acid; Cell Culture Techniques; Enzyme Inhib | 2017 |
Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cross-Sectional Studies; Female; Hemoglobins | 2017 |
Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Erythrocyte Deformabil | 2008 |
Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia.
Topics: Adolescent; beta-Thalassemia; Case-Control Studies; Echocardiography; Female; Humans; Hydroxyurea; H | 2009 |
DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Azacitidine; beta-Thalassemia; Decitabine; DNA (Cytosine | 2008 |
Hydroxyurea therapy in 49 patients with major beta-thalassemia.
Topics: Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Child; Dose-Response Relationship, Drug; F | 2009 |
Extramedullary hematopoiesis with spinal cord compression in a child with thalassemia intermedia.
Topics: beta-Thalassemia; Blood Group Antigens; Child; Combined Modality Therapy; Contraindications; Cytotox | 2009 |
Treatment with hydroxyurea in a patient compound heterozygote for a high oxygen affinity hemoglobin and beta-thalassemia minor.
Topics: Adult; beta-Thalassemia; Follow-Up Studies; Hemoglobins, Abnormal; Heterozygote; Humans; Hydroxyurea | 2009 |
Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Female; Fetus; Humans; Hydroxyure | 2010 |
Evaluation of the genetic basis of phenotypic heterogeneity in north Indian patients with thalassemia major.
Topics: Age of Onset; Alleles; beta-Globins; beta-Thalassemia; Child, Preschool; Deoxyribonucleases, Type II | 2010 |
Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male | 2010 |
Red cells playing as activated platelets in thalassemia intermedia.
Topics: Aspirin; beta-Thalassemia; Blood Platelets; Erythrocytes; Hematology; Hemoglobins; Humans; Hydroxyur | 2010 |
Coexistence of β-thalassemia and polycythemia vera.
Topics: Aged; beta-Thalassemia; Female; Hematologic Tests; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Po | 2011 |
Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study.
Topics: Adolescent; Adult; Antimetabolites; beta-Thalassemia; Case-Control Studies; Child; Child, Preschool; | 2011 |
Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Chelation Therapy; | 2011 |
Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Topics: Adolescent; Adult; Antimetabolites; beta-Globins; beta-Thalassemia; Child; Child, Preschool; Dose-Re | 2012 |
Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea.
Topics: Adolescent; Adult; Antineoplastic Agents; beta-Thalassemia; Case-Control Studies; Child; Estradiol; | 2012 |
The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Female; Fetal Hemoglobin; Gene Freq | 2012 |
Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Brain Diseases; Cerebrum; Child; Cohort Stud | 2012 |
A single nucleotide polymorphism in the HBBP1 gene in the human β-globin locus is associated with a mild β-thalassemia disease phenotype.
Topics: Alleles; beta-Globins; beta-Thalassemia; Gene Frequency; Genetic Association Studies; Genetic Linkag | 2012 |
KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Topics: 3' Untranslated Regions; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Early Gr | 2012 |
Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.
Topics: Adaptation, Biological; ADP-Ribosylation Factors; Apoptosis; beta-Thalassemia; Cell Differentiation; | 2013 |
Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis.
Topics: Adult; beta-Thalassemia; Follow-Up Studies; Granuloma; Hematopoiesis; Homozygote; Humans; Hydroxyure | 2002 |
The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Topics: Adolescent; Antisickling Agents; beta-Thalassemia; Fetal Hemoglobin; Humans; Hydroxyurea; Superoxide | 2002 |
Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta0 thalassemia.
Topics: Antisickling Agents; beta-Thalassemia; Child; Erythropoietin; Female; Hepatomegaly; Humans; Hydroxyu | 2002 |
Colonic pseudo-obstruction in sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Colonic Pseudo-Obs | 2003 |
Flow cytometric analysis of hydroxyurea effects on fetal hemoglobin production in cultures of beta-thalassemia erythroid precursors.
Topics: Adult; beta-Thalassemia; Cells, Cultured; Dose-Response Relationship, Drug; Female; Fetal Hemoglobin | 2003 |
The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Coagulation; Blood Proteins; Child; | 2003 |
Polycythemia vera with uncommon presentations.
Topics: Adult; Aged; Anemia, Hypochromic; beta-Thalassemia; Case Management; Disease Progression; Genotype; | 2003 |
Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Topics: beta-Thalassemia; Blood Transfusion; Cells, Cultured; Chromatography, High Pressure Liquid; Codon; D | 2006 |
Hydroxyurea use in Lebanese patients with beta-thalassemia intermedia.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Combined Modality Therapy; Genetic Variation; Humans; Hy | 2006 |
The bone density of thalassemic patients of Boo Ali Sina Hospital, Sari, Iran in 2002 does hydroxyurea help?
Topics: Absorptiometry, Photon; Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Bone Density; Case | 2004 |
Paraplegia due to spinal cord compression by extramedullary erythropoietic tissue in a thalassaemia intermedia patient with gynecomastia secondary to cirrhosis: successful treatment with hydroxyurea.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Erythropoiesis; Gynecomastia; Humans; Hydroxyurea; Liv | 2004 |
Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications.
Topics: Adult; beta-Thalassemia; Female; Humans; Hydroxyurea; Leg Ulcer; Male | 2004 |
Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia.
Topics: Adult; Atrial Fibrillation; beta-Thalassemia; Blood Transfusion; Chest Tubes; Combined Modality Ther | 2006 |
Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Deferiprone; Drug Therapy, Combination; Humans; Hydrox | 2006 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
A review of cis-trans interplay between DNA sequences 5' to the (G)gamma- and beta-globin genes among Hb F-Malta-I heterozygotes/homozygotes and beta-thalassemia homozygotes/compound heterozygotes, and the effects of hydroxyurea on the Hb F/F-erythrocyte;
Topics: beta-Thalassemia; DNA; Erythrocytes; Fetal Hemoglobin; Genetic Carrier Screening; Globins; Homozygot | 2007 |
Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Case-Control Studies; Female; Ferritins; Humans; Hydro | 2007 |
Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Topics: Adolescent; Adult; Algeria; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Female; Gl | 2007 |
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; B | 2008 |
Response to hydroxyurea therapy in beta-thalassemia.
Topics: Adolescent; Adult; alpha-Thalassemia; beta-Thalassemia; Blood Transfusion; Child; Cohort Studies; Co | 2008 |
Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
Topics: Adolescent; beta-Thalassemia; Blood Chemical Analysis; Child; Enzyme Inhibitors; Female; Hemoglobins | 2008 |
Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients.
Topics: beta-Thalassemia; Cells, Cultured; Erythroid Cells; Fetal Hemoglobin; Globins; Hemoglobins, Abnormal | 2008 |
Pharmacologic treatment of thalassemia intermedia with hydroxyurea.
Topics: Administration, Oral; Adult; beta-Thalassemia; Erythrocyte Indices; Female; Fetal Hemoglobin; Hemogl | 1994 |
Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Cell Division; Cells, Cultured; Drug Synergism; Erythroid Pre | 1995 |
Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis.
Topics: beta-Thalassemia; Female; Globins; Hemoglobins; Humans; Hydroxyurea; Leukocyte Count; Male; Platelet | 1995 |
Myeloproliferative disorders in two New Jersey families.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; beta-Thalassemia; Carcinoma, Non-Small-Cell Lung; Female; | 1995 |
Reversing ontogeny.
Topics: Anemia, Sickle Cell; Arginine; beta-Thalassemia; Butyrates; Fetal Hemoglobin; Globins; Humans; Hydro | 1993 |
Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Drug Synergism; Drug Therapy, Combination; Erythrocyte | 1993 |
Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Cells, Cultured; Erythroid Precursor Cells; Fetal Hemoglobin; | 1993 |
Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
Topics: Anemia, Sickle Cell; Azacitidine; beta-Thalassemia; Blotting, Northern; Butyrates; Butyric Acid; Cel | 1993 |
Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
Topics: Adult; beta-Thalassemia; Child; Female; Gene Expression Regulation; Globins; Hemoglobins; Humans; Hy | 1994 |
Improvement of mouse beta thalassaemia by hydroxyurea.
Topics: Animals; beta-Thalassemia; Blood Proteins; Erythrocyte Deformability; Erythrocyte Indices; Globins; | 1993 |
Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.
Topics: Animals; beta-Thalassemia; Body Water; Calcimycin; Calcium; Calcium Channel Blockers; Chlorides; Clo | 1996 |
Hydroxyurea therapy in children severely affected with sickle cell disease.
Topics: Adolescent; alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Do | 1996 |
[Study of hemoglobinopathies found in Belgium].
Topics: Anemia, Sickle Cell; Antisickling Agents; Belgium; beta-Thalassemia; Bone Marrow Transplantation; Ch | 1995 |
Successful use of hydroxyurea in beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Hemoglobins; Humans; Hydroxyurea | 1997 |
Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia.
Topics: Adult; beta-Thalassemia; Chromatography, High Pressure Liquid; Electrophoresis, Polyacrylamide Gel; | 1997 |
Treatment of thalassaemia major with phenylbutyrate and hydroxyurea.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Child; Female; Humans; Hydroxyurea; | 1997 |
Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia.
Topics: Adult; beta-Thalassemia; Erythropoiesis; Fetal Hemoglobin; Hematopoiesis, Extramedullary; Humans; Hy | 1998 |
Increase in hemoglobin concentration during therapy with hydroxyurea in Cooley's anemia.
Topics: beta-Thalassemia; Child; Consanguinity; Globins; Hemoglobins; Humans; Hydroxyurea; Male; Point Mutat | 1998 |
Preliminary report: hydroxyurea produces significant clinical response in thalassemia intermedia.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Child, Preschool; Female; Hemoglobin E; Humans; Hydroxyu | 1998 |
Hydroxyurea treatment in thalassaemia.
Topics: beta-Thalassemia; Fetal Hemoglobin; Hematopoiesis, Extramedullary; Humans; Hydroxyurea | 1998 |
Bone pain in thalassaemia: assessment of DEXA and MRI findings.
Topics: Absorptiometry, Photon; Adult; Aging; beta-Thalassemia; Blood Transfusion; Bone and Bones; Bone Dens | 1998 |
Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
Topics: Adult; beta-Thalassemia; Cambodia; Child; Child, Preschool; China; Female; Fetal Hemoglobin; Hemoglo | 1999 |
[beta-thalassemia minor diagnosed in a patient with chronic myelogenous leukemia during hydroxyurea therapy].
Topics: Antineoplastic Agents; beta-Thalassemia; Globins; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelog | 2000 |
Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters.
Topics: Adult; beta-Thalassemia; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Italy; Male; Paraparesi | 2000 |
Hydroxyurea promotes the reduction of spontaneous BFU-e to normal levels in SS and S/beta thalassemic patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Cell Count; Cell Differentiation; | 2001 |
Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Bone Marrow Transplantation; Child; Combined Modality Therapy | 2001 |
The studies of hemoglobinopathies and thalassemia in China--the experiences in Shanghai Institute of Medical Genetics.
Topics: beta-Thalassemia; China; Globins; Hemoglobinopathies; Heterozygote; Homozygote; Humans; Hydroxyurea; | 2001 |
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Humans; Hydroxyurea; Leukem | 2002 |
Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Erythroid Precursor Cells; Erythropoietin; | 2000 |